Mereo BioPharma Faces Class Action Lawsuit Over Misleading Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MREO?
Source: Globenewswire
- Class Action Filed: Wolf Haldenstein Adler Freeman & Herz LLP has announced a class action lawsuit against Mereo BioPharma on behalf of all investors who purchased ADSs between June 5, 2023, and December 26, 2025, with a deadline of April 6, 2026, for lead plaintiff applications.
- False Statements Allegations: Investors allege that Mereo and certain executives made materially false and misleading statements regarding the success likelihood of its Phase 3 clinical trials for setrusumab, claiming statistical significance would be achieved, while concealing that neither trial was on track to meet its primary endpoint.
- Stock Price Collapse: Following a December 29, 2025, disclosure that neither ORBIT nor COSMIC achieved statistical significance, Mereo's stock plummeted from $2.31 to $0.29 in a single trading session, representing an over 87% loss in shareholder value.
- Law Firm's Expertise: Founded in 1888, Wolf Haldenstein Adler Freeman & Herz LLP brings over 125 years of legal expertise in securities litigation, committed to seeking justice for investors harmed by misrepresented statements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MREO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MREO
Wall Street analysts forecast MREO stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.389
Low
0.50
Averages
2.08
High
5.00
Current: 0.389
Low
0.50
Averages
2.08
High
5.00
About MREO
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Filed Against Mereo BioPharma Group plc
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Mereo BioPharma Group plc, seeking damages for investors who purchased securities between June 5, 2023, and December 26, 2025, reflecting strong investor response to potential fraud allegations.
- False Statements Allegations: The complaint alleges that throughout the class period, defendants made overly optimistic statements while concealing significant adverse facts regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints, potentially undermining investor confidence.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by April 6, 2026, to share in any potential recovery from the lawsuit, indicating the legal team's commitment to protecting investor rights.
- No-Cost Legal Services: The law firm offers services on a contingency fee basis, meaning they will only charge fees if they successfully recover funds, thereby reducing financial risk for investors and encouraging their participation in the lawsuit.
See More
Mereo BioPharma Faces Class Action Lawsuit Over Misleading Trial Results
- Class Action Filed: Wolf Haldenstein Adler Freeman & Herz LLP has announced a class action lawsuit against Mereo BioPharma on behalf of all investors who purchased ADSs between June 5, 2023, and December 26, 2025, with a deadline of April 6, 2026, for lead plaintiff applications.
- False Statements Allegations: Investors allege that Mereo and certain executives made materially false and misleading statements regarding the success likelihood of its Phase 3 clinical trials for setrusumab, claiming statistical significance would be achieved, while concealing that neither trial was on track to meet its primary endpoint.
- Stock Price Collapse: Following a December 29, 2025, disclosure that neither ORBIT nor COSMIC achieved statistical significance, Mereo's stock plummeted from $2.31 to $0.29 in a single trading session, representing an over 87% loss in shareholder value.
- Law Firm's Expertise: Founded in 1888, Wolf Haldenstein Adler Freeman & Herz LLP brings over 125 years of legal expertise in securities litigation, committed to seeking justice for investors harmed by misrepresented statements.
See More
Mereo BioPharma Faces Class Action Lawsuit Over Securities Fraud
- Class Action Initiated: Levi & Korsinsky LLP has notified investors that Mereo BioPharma Group plc is facing a class action lawsuit aimed at recovering losses for investors adversely affected by alleged securities fraud between June 5, 2023, and December 26, 2025.
- False Statements Exposed: The complaint alleges that defendants made overwhelmingly positive statements to investors while concealing material adverse facts regarding the true state of the Phase 3 ORBIT and COSMIC programs, which misled investors and affected their decision-making.
- Study Results Fail to Meet Standards: On December 29, 2025, Mereo announced that neither the ORBIT nor COSMIC Phase 3 studies achieved statistical significance, failing to meet their primary endpoint of reducing clinical fracture rates compared to placebo or bisphosphonates, despite improvements in bone mineral density.
- Stock Price Plummets: Following the negative announcement, Mereo's ADS price fell dramatically from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, representing a decline of over 87.7%, severely impacting investor asset values.
See More
Mereo BioPharma Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Mereo BioPharma Group plc, encouraging those who purchased shares between June 5, 2023, and December 26, 2025, to contact the firm regarding potential lead plaintiff appointment for recovery.
- Allegations: The complaint alleges that Mereo BioPharma made misleading statements about the Phase 3 ORBIT and COSMIC programs, concealing the fact that neither study achieved its primary endpoints, which misled investors about the company's performance.
- Stock Price Collapse: Following the December 29, 2025, announcement that neither the ORBIT nor COSMIC studies achieved statistical significance, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share, representing a staggering decline of over 87.7%.
- Steps for Participation: Shareholders must register by April 6, 2026, to participate in the class action lawsuit, and upon registration, they will receive updates on the case's progress without any cost or obligation to participate.
See More
Class Action Notice for Mereo BioPharma Investors
- Class Action Initiation: The Portnoy Law Firm advises Mereo BioPharma Group plc investors of a class action for those who purchased securities between June 5, 2023, and December 26, 2025, with a deadline for lead plaintiff motions set for April 6, 2026.
- False Statements Revealed: The complaint alleges that Mereo misled investors by providing overly positive statements while concealing adverse facts regarding the Phase 3 ORBIT and COSMIC programs, which significantly impacted investor decisions.
- Poor Study Results: On December 29, 2025, Mereo announced that neither the ORBIT nor COSMIC studies achieved statistical significance, failing to meet their primary endpoint of reducing clinical fracture rates, despite improvements in bone mineral density.
- Stock Price Collapse: Following the negative announcement, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, representing a decline of over 87.7%, severely affecting investor asset values.
See More
Class Action Lawsuit Announced for Mereo BioPharma
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, indicating significant legal risks for the company and potential financial repercussions for investors.
- Compensation Mechanism: Investors may receive compensation through a contingency fee arrangement without upfront costs, which alleviates financial burdens and encourages more affected parties to join the lawsuit, thereby enhancing the collective strength of the claim.
- Lawsuit Background: The lawsuit alleges that Mereo BioPharma misled investors regarding the Phase 3 Orbit and COSMIC studies for setrusumab, as the actual results did not meet the optimistic projections, leading to purchases at artificially inflated prices and highlighting serious deficiencies in the company's disclosure practices.
- Law Firm's Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in navigating complex legal challenges in the financial sector.
See More
Class Action Filed Against Mereo BioPharma Group plc
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Mereo BioPharma Group plc, seeking damages for investors who purchased securities between June 5, 2023, and December 26, 2025, reflecting strong investor response to potential fraud allegations.
- False Statements Allegations: The complaint alleges that throughout the class period, defendants made overly optimistic statements while concealing significant adverse facts regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints, potentially undermining investor confidence.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by April 6, 2026, to share in any potential recovery from the lawsuit, indicating the legal team's commitment to protecting investor rights.
- No-Cost Legal Services: The law firm offers services on a contingency fee basis, meaning they will only charge fees if they successfully recover funds, thereby reducing financial risk for investors and encouraging their participation in the lawsuit.
See More
Mereo BioPharma Faces Class Action Lawsuit Over Misleading Trial Results
- Class Action Filed: Wolf Haldenstein Adler Freeman & Herz LLP has announced a class action lawsuit against Mereo BioPharma on behalf of all investors who purchased ADSs between June 5, 2023, and December 26, 2025, with a deadline of April 6, 2026, for lead plaintiff applications.
- False Statements Allegations: Investors allege that Mereo and certain executives made materially false and misleading statements regarding the success likelihood of its Phase 3 clinical trials for setrusumab, claiming statistical significance would be achieved, while concealing that neither trial was on track to meet its primary endpoint.
- Stock Price Collapse: Following a December 29, 2025, disclosure that neither ORBIT nor COSMIC achieved statistical significance, Mereo's stock plummeted from $2.31 to $0.29 in a single trading session, representing an over 87% loss in shareholder value.
- Law Firm's Expertise: Founded in 1888, Wolf Haldenstein Adler Freeman & Herz LLP brings over 125 years of legal expertise in securities litigation, committed to seeking justice for investors harmed by misrepresented statements.
See More
Mereo BioPharma Faces Class Action Lawsuit Over Securities Fraud
- Class Action Initiated: Levi & Korsinsky LLP has notified investors that Mereo BioPharma Group plc is facing a class action lawsuit aimed at recovering losses for investors adversely affected by alleged securities fraud between June 5, 2023, and December 26, 2025.
- False Statements Exposed: The complaint alleges that defendants made overwhelmingly positive statements to investors while concealing material adverse facts regarding the true state of the Phase 3 ORBIT and COSMIC programs, which misled investors and affected their decision-making.
- Study Results Fail to Meet Standards: On December 29, 2025, Mereo announced that neither the ORBIT nor COSMIC Phase 3 studies achieved statistical significance, failing to meet their primary endpoint of reducing clinical fracture rates compared to placebo or bisphosphonates, despite improvements in bone mineral density.
- Stock Price Plummets: Following the negative announcement, Mereo's ADS price fell dramatically from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, representing a decline of over 87.7%, severely impacting investor asset values.
See More
Mereo BioPharma Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Mereo BioPharma Group plc, encouraging those who purchased shares between June 5, 2023, and December 26, 2025, to contact the firm regarding potential lead plaintiff appointment for recovery.
- Allegations: The complaint alleges that Mereo BioPharma made misleading statements about the Phase 3 ORBIT and COSMIC programs, concealing the fact that neither study achieved its primary endpoints, which misled investors about the company's performance.
- Stock Price Collapse: Following the December 29, 2025, announcement that neither the ORBIT nor COSMIC studies achieved statistical significance, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share, representing a staggering decline of over 87.7%.
- Steps for Participation: Shareholders must register by April 6, 2026, to participate in the class action lawsuit, and upon registration, they will receive updates on the case's progress without any cost or obligation to participate.
See More
Class Action Notice for Mereo BioPharma Investors
- Class Action Initiation: The Portnoy Law Firm advises Mereo BioPharma Group plc investors of a class action for those who purchased securities between June 5, 2023, and December 26, 2025, with a deadline for lead plaintiff motions set for April 6, 2026.
- False Statements Revealed: The complaint alleges that Mereo misled investors by providing overly positive statements while concealing adverse facts regarding the Phase 3 ORBIT and COSMIC programs, which significantly impacted investor decisions.
- Poor Study Results: On December 29, 2025, Mereo announced that neither the ORBIT nor COSMIC studies achieved statistical significance, failing to meet their primary endpoint of reducing clinical fracture rates, despite improvements in bone mineral density.
- Stock Price Collapse: Following the negative announcement, Mereo's ADS price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, representing a decline of over 87.7%, severely affecting investor asset values.
See More
Class Action Lawsuit Announced for Mereo BioPharma
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, indicating significant legal risks for the company and potential financial repercussions for investors.
- Compensation Mechanism: Investors may receive compensation through a contingency fee arrangement without upfront costs, which alleviates financial burdens and encourages more affected parties to join the lawsuit, thereby enhancing the collective strength of the claim.
- Lawsuit Background: The lawsuit alleges that Mereo BioPharma misled investors regarding the Phase 3 Orbit and COSMIC studies for setrusumab, as the actual results did not meet the optimistic projections, leading to purchases at artificially inflated prices and highlighting serious deficiencies in the company's disclosure practices.
- Law Firm's Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and influence in navigating complex legal challenges in the financial sector.
See More
